Volume 15, Issue 8, Pages 874-885 (July 2014) High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial  Prof Gordon Cook, PhD, Cathy Williams, MD, Prof Julia M Brown, PhD, David A Cairns, PhD, Prof Jamie Cavenagh, MD, Prof John A Snowden, A John Ashcroft, PhD, Marie Fletcher, BSc, Chris Parrish, MBBS, Prof Kwee Yong, PhD, Jim Cavet, PhD, Hanna Hunter, MD, Jenny M Bird, MD, Anna Chalmers, BSc, Sheila O'Connor, PhD, Prof Mark T Drayson, PhD, Prof Treen C M Morris, MD  The Lancet Oncology  Volume 15, Issue 8, Pages 874-885 (July 2014) DOI: 10.1016/S1470-2045(14)70245-1 Copyright © 2014 Elsevier Ltd Terms and Conditions

Figure 1 Trial profile ASCT=autologous stem-cell transplant. PBSC=peripheral blood stem cell. *The 26 patients who had sufficient stem cells stored still underwent PBSC mobilisation and harvest. The Lancet Oncology 2014 15, 874-885DOI: (10.1016/S1470-2045(14)70245-1) Copyright © 2014 Elsevier Ltd Terms and Conditions

Figure 2 Progression and survival outcomes in the intention-to-treat population Kaplan-Meier curves were plotted for time to progression (A), defined as time from randomisation to the first assessment showing disease progression (deaths not due to disease progression were censored); progression-free survival (B), defined as time from randomisation to first assessment showing disease progression or death from any cause; and overall survival (C), defined as the time from randomisation to death from any cause. ASCT=autologous stem-cell transplant. The Lancet Oncology 2014 15, 874-885DOI: (10.1016/S1470-2045(14)70245-1) Copyright © 2014 Elsevier Ltd Terms and Conditions

Figure 3 Subgroup analysis of time to progression HRs for risk of disease progression in the melphalan plus salvage ASCT group compared with the cyclophosphamide group. PAD=bortezomib, doxorubicin, and dexamethasone. sCR=stringent complete response. CR=complete response. VGPR=very good partial response. PR=partial response. iFISH=interphase fluorescence in-situ hybridisation. HR=hazard ratio. *Adverse risk was defined by the presence of a t(4;14) translocation, t(14;16) translocation, or TP53 deletion; standard risk was defined by the absence of adverse markers. †Numbers for each subgroup do not add up to 174 overall because not all patients had the information needed for the subgroup analysis. The Lancet Oncology 2014 15, 874-885DOI: (10.1016/S1470-2045(14)70245-1) Copyright © 2014 Elsevier Ltd Terms and Conditions